Request for Information (RFI) Special Notice DARPA-SN-26-96 Advancing Autonomous Science for Biological Applications DARPA BTO

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Application deadline: July 22, 2026, at 5:00 p.m. Eastern Time (ET). This is a Request for Information (RFI) issued by the Defense Advanced Research Projects Agency (DARPA) Biological Technology Office (BTO)—not a funding opportunity or solicitation for proposals. DARPA is seeking input from the scientific and technical community on the current state of autonomous science for biological applications, key technical challenges, and future investment opportunities that could inform future DARPA programs. Organizations with expertise in autonomous science, AI, robotics, laboratory automation, and related technologies should consider submitting a response before July 22, 2026, at 5:00 p.m. Eastern Time (ET) to help shape potential future research initiatives.

How much funding would I receive?

This RFI does not provide funding. Award amounts, contract values, or grant funding are not specified because this is an information-gathering request rather than a solicitation for proposals. This information can be used to apply to the DARPA BTO Broad Agency Announcement for awards under $2 million.

REQUESTED INFORMATION:

Responses should address Informatics Technologies, Physical Technologies, or Both Informatics and Physical Technologies for autonomous science. In each case, a response must address at least one of the following research areas:

1. Current state of the art of autonomous science and transformational enabling technologies to advance that state of the art

• Key existing enabling technologies broadly transferrable across scientific workflows.

• Technologies in development that will be transformational in enabling autonomous science.

• Metrics of success for judging the current state of the art and emerging technologies to surpass it (e.g., throughput, reproducibility, power usage, continuous runtime, cost per assay, etc.).

2. Key technical, organizational, or operational bottlenecks in deploying autonomous science at scale or in new domains

• Challenges to enabling rapid development and exchange of new autonomous workflows, including equipment or assays that provide unique challenges to automation.

• Challenges to interoperability between laboratories and the exchange of data and protocols.

• Measures of success in promoting more efficient, effective, and portable workflow development.

3. Application areas in which new investments could have the greatest impact and best demonstrate the unique advantages of autonomous science to solve problems not amenable to conventional approaches

• Problems of national interest where autonomous science can achieve results infeasible via conventional science, including specific applications for national security.

• Enabling technologies available or emerging to achieve those results.

• Metrics for establishing improvement over conventional approaches.

• Current commercialization strategies and business cases for future development of autonomous science.

4. Safety and security considerations in the operation of highly automated laboratories and ways these might be addressed, for example through simulation, AI digital twins, or formal verification

• Risks to safety and security in the operation of autonomous laboratories.

• Current safeguards, system-level security, traceability, and other approaches to biosecurity.

• Enabling technologies to resolve these risks.

• Measures of success for safe operation.

5. New technologies, opportunities, and challenges for maximizing productive interaction between human operators and autonomous agents in hybrid human-AI workflows

• Applications of national interest that can be achieved only by humans augmented by autonomous scientific facilities.

• Key barriers to productive interaction between human scientists and autonomous laboratories or their AI agents.

• Enabling technologies to overcome these barriers.

• Metrics of success demonstrating the advancement of human-machine partnering over unassisted human or purely autonomous systems.

Are there any additional benefits I would receive?

Submitting a response gives organizations an opportunity to:

• Provide input that may influence future DARPA program development.

• Share perspectives on the current state of autonomous science in biological domains.

• Highlight emerging technologies, technical challenges, commercialization strategies, and national security applications.

Entities that have not previously worked with DARPA are also encouraged to engage with DARPAConnect, which offers educational resources, one-on-one guidance, and outreach to help organizations understand how to engage with DARPA.

What is the timeline to apply and when would I receive funding?

Response deadline: July 22, 2026, at 5:00 p.m. Eastern Time (ET).

Responses must be submitted electronically in PDF format to AutoSci-RFI@darpa.mil.

There is no funding timeline because this is an RFI rather than a funding opportunity. DARPA states that responses may be used to inform future program development, but no subsequent solicitation schedule is provided.

Where does this funding come from?

This RFI was issued by the Defense Advanced Research Projects Agency (DARPA), Biological Technology Office (BTO).

Because this is an RFI, no funding source or funding program is specified.

Who is eligible to apply?

DARPA welcomes responses from all capable sources, including but not limited to:

• Private companies

• Public companies

• Individuals

• Universities

• University-affiliated research centers

• Not-for-profit research institutions

• U.S. Government-sponsored laboratories

Who is not eligible to apply?

The RFI does not specify any excluded applicant categories.

However:

• Classified information must not be submitted.

• DARPA encourages submission of non-proprietary information, and proprietary information must be clearly marked if included.

What companies and projects are likely to win?

This is not a competitive funding opportunity, so there are no awards or winners.

DARPA is seeking responses addressing one or more research areas related to autonomous science, including:

• State-of-the-art autonomous science technologies

• Technical, organizational, and operational bottlenecks

• High-impact application areas

• Safety and security for autonomous laboratories

• Human-autonomous system collaboration

Responses may focus on:

• Informatics Technologies

• Physical Technologies

• Both Informatics and Physical Technologies

How competitive will this solicitation be?

DARPA states that this RFI is issued solely for information and program planning purposes and does not constitute a formal solicitation for proposals or proposal abstracts. Responses are voluntary and will not result in a contract or funding.

Are there any restrictions I should know about?

Key submission requirements include:

• Responses are limited to 7 pages maximum using 12-point font, 1-inch margins, and standard letter-sized pages.

• Responses must be submitted as an unprotected Microsoft Word document or PDF.

• Classified information must not be included.

• Proprietary information must be clearly labeled.

• DARPA will not reimburse response preparation costs.

• Responses are voluntary.

• Proposal abstracts or formal proposals submitted in response to this RFI will be disregarded.

• DARPA is under no obligation to acknowledge or provide feedback on submissions.

How long will it take me to prepare an application?

Responses must include:

• A one-page cover page

• Up to three pages describing the technical approach

• One page of references

• Optional summary slides

Organizations should also identify which technology category and research area(s) their response addresses.

How can BW&CO help?

BW&CO can help organizations prepare a concise, DARPA-ready RFI response by:

• Aligning your response with DARPA's requested research areas.

• Clearly articulating technical capabilities, challenges, and proposed solutions.

• Developing commercialization and national security narratives where supported by your technical work.

• Ensuring compliance with formatting, page limits, and submission requirements.

• Producing a polished submission designed to communicate your organization's expertise effectively.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Reconstructive Transplant Research Program (RTRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Reconstructive Transplant Research Program (RTRP) Concept Award supports highly innovative, high-risk research that could open new directions in reconstructive transplantation. The program is designed to fund new concepts and untested theories rather than incremental advances to existing work. Projects must address at least one FY26 RTRP Focus Area and be relevant to improving outcomes for catastrophically injured Service Members, Veterans, their families, caregivers, clinicians, and the American public. Clinical trials are not allowed.

This is a relatively small, early-stage funding opportunity intended to help researchers generate foundational insights that could lead to future development and larger follow-on efforts. The Defense Health Agency expects to fund approximately three awards. The application deadline is 11:59 p.m. ET, September 16, 2026. Organizations interested in applying should begin preparing immediately because a required Letter of Intent must be submitted first by 5:00 p.m. Eastern Time (ET), September 2, 2026.

How much funding would I receive?

Applicants may request up to $200,000 in total costs for the entire project period. The maximum period of performance is 18 months.

The FY26 RTRP expects to allocate approximately $0.6 million to fund approximately three Concept Award applications.

Cost sharing is not required.

What could I use the funding for?

Funding is intended to support highly innovative research addressing important problems in reconstructive transplantation and vascularized composite allotransplantation (VCA). The award specifically supports exploration of new concepts and untested theories rather than continuation of established research programs.

Projects must address at least one of the following FY26 RTRP Focus Areas:

• Improve or optimize VCA immunosuppression.

• Identify and/or validate prognostic or diagnostic biomarkers, methods, or tools for monitoring VCA graft rejection and immunosuppression.

• Advance VCA preservation strategies.

• Develop tools for measuring VCA outcomes, including performance-based, patient-reported, and neurocognitive outcomes.

Allowable costs may include:

• Research activities supporting the proposed project.

• Travel supporting multi-institutional collaborations.

• Travel for one investigator to present project findings at one scientific or technical meeting per year.

• Required travel for the Principal Investigator to present results at one Department of War-sponsored meeting during the award period.

Are there any additional benefits I would receive?

In addition to funding, awardees gain the opportunity to conduct research within a Department of Defense-funded program focused on advancing reconstructive transplantation and improving outcomes for catastrophically injured Service Members and Veterans.

Award recipients may also be invited to present project progress at annual RTRP In-Progress Review meetings.

What is the timeline to apply and when would I receive funding?

Key dates include:

• Letter of Intent deadline: 5:00 p.m. Eastern Time (ET), September 2, 2026

• Full application deadline: 11:59 p.m. ET, September 16, 2026

• End of application verification period: 5:00 p.m. ET, September 21, 2026

• Peer review: November 2026

• Programmatic review: January 2027

Awards supported with FY26 funds will be made no later than September 30, 2027.

Where does this funding come from?

This funding opportunity is offered through the Defense Health Agency Contracting Activity (DHACA) and managed by the Congressionally Directed Medical Research Programs (CDMRP) as part of the Reconstructive Transplant Research Program (RTRP).

Congress initiated the RTRP in 2012 to support research that refines reconstructive transplantation approaches and expands access to reconstructive transplants and immunotherapy. The FY26 appropriation for the RTRP is $12 million.

Who is eligible to apply?

Eligible applicant organizations include:

• Extramural and intramural U.S. Department of War organizations.

• Foreign organizations.

• Domestic organizations.

• For-profit organizations.

• Nonprofit organizations.

• Public entities.

• Private entities.

Eligible Principal Investigators include:

• Investigators at or above the level of postdoctoral fellow.

• Investigators affiliated with an eligible organization.

• Investigators regardless of ethnicity, nationality, or citizenship status.

• Investigators from academic or non-academic organizations.

An investigator may serve as PI on no more than two FY26 RTRP Concept Award applications.

Who is not eligible to apply?

The solicitation states that:

• Individuals cannot receive awards directly because awards are made to organizations.

• Investigators below the level of postdoctoral fellow are not eligible to serve as PI.

• Investigators serving as PI on more than two FY26 RTRP Concept Award applications are not eligible beyond the first two submissions received.

Applications may also be administratively withdrawn if:

• A clinical trial is proposed.

• Human subjects or specimen studies do not qualify for exempt or expedited review.

• The PI does not meet eligibility requirements.

• Required pre-application materials are not submitted.

What companies and projects are likely to win?

The program is seeking projects that are:

• Highly innovative.

• High-risk with the potential to reveal new avenues of investigation.

• Focused on at least one FY26 RTRP Focus Area.

• Relevant to military health and catastrophic injury recovery.

• Supported by a strong scientific rationale despite the absence of preliminary data.

• Designed with rigorous and reproducible research methods.

Applications leveraging findings from solid organ transplantation for testing in VCA may be competitive when the rationale and potential benefits are clearly justified.

The review criteria place the greatest emphasis on:

1. Innovation

2. Relevance

3. Research Strategy and Feasibility

4. Personnel

5. Transition Plan

6. Research Sharing Plan

7. Budget

8. Environment

9. Application Presentation

How competitive will this solicitation be?

This appears to be a highly competitive opportunity.

The program expects to fund approximately three awards from a total funding pool of approximately $0.6 million.

The solicitation also notes that since FY15, the RTRP Concept Award mechanism has received 196 applications, with 26 recommended for funding.

Are there any restrictions I should know about?

Key restrictions include:

• Clinical trials are not allowed.

• Preliminary data cannot be included.

• Research involving human subjects or specimens must qualify for exempt status or expedited review.

• Projects involving painful research using domestic cats or dogs are not supported except for studies relating to military or service animals.

• Classified research data or research likely to generate classified outcomes may result in withdrawal.

• Duplicate submissions of the same research project within the RTRP during the same fiscal year are prohibited.

How long will it take me to prepare an application?

The application process includes both:

1. A required Letter of Intent submission.

2. A full application package.

The solicitation does not specify how long preparation will take. However, applicants must prepare multiple application components, including a Project Narrative, Statement of Work, Innovation Statement, Post-Award Transition Plan, budget materials, supporting documentation, and other required forms.

How can BW&CO help?

BW&CO can help your team:

• Evaluate whether your concept aligns with one or more FY26 RTRP Focus Areas.

• Position your project around the program’s primary review criteria, particularly innovation and military relevance.

• Develop a compliant Letter of Intent and full application package.

• Build a compelling research strategy and transition plan.

• Prepare budgets, supporting documentation, and submission materials.

• Manage the application process through submission and compliance review.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Rare Cancers Research Program (RCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Rare Cancers Research Program (RCRP) is a Department of Defense-funded grant program that supports research on cancers affecting six or fewer persons per 100,000 people per year in the United States. The program aims to improve outcomes for people with rare cancers through discovery, community building, and expansion of knowledge across the cancer landscape. Research must be relevant to Service Members, Veterans, military beneficiaries, and the American public.
RCRP offers three separate funding opportunities in FY26:

• Concept Award – supports highly innovative, untested, potentially groundbreaking ideas.
• Idea Development Award – supports promising research ideas that are ready for further development and could generate high-impact findings.
• Resource and Community Development Award – supports development of research resources, datasets, infrastructure, and community-building platforms for rare cancers research.

Applicants interested in the Idea Development Award or Resource and Community Development Award must submit a required preproposal by 5:00 p.m. Eastern Time (ET), August 19, 2026. Applicants interested in the Concept Award must submit a required Letter of Intent by 5:00 p.m. Eastern Time (ET), September 16, 2026, and a full application by 11:59 p.m. ET, September 30, 2026.

How much funding would I receive?

Funding depends on the award mechanism selected:

Concept Award

• Up to $140,000 total costs

• Maximum period of performance: 2 years

• Approximately 18 awards expected

Idea Development Award

• Up to $490,000 total costs

• Maximum period of performance: 3 years

• Approximately 15 awards expected

Resource and Community Development Award

• Up to $1.12 million total costs

• Maximum period of performance: 4 years

• Approximately 5 awards expected

What could I use the funding for?

Projects must address rare cancers and align with one or more FY26 RCRP focus areas.

Concept Award and Idea Development Award focus areas

• Biology

• Preclinical Research Models

• Therapy, including drug repurposing

• Artificial Intelligence (AI) and Machine Learning (ML) Models
  Resource and Community Development Award focus areas

• Platform Development

• Artificial Intelligence (AI) and Machine Learning (ML) Models

Examples of activities supported under the Resource and Community Development Award include:

• Biospecimen repositories

• Patient registries

• Databases and centralized data-sharing platforms

• Omics resources

• Longitudinal natural history studies

• Resource-sharing infrastructure

• AI/ML-enabled discovery platforms

Are there any additional benefits I would receive?

In addition to funding, successful applicants gain access to a nationally recognized Department of Defense cancer research program focused on advancing rare cancers research and improving outcomes for patients, Service Members, Veterans, and their families.

The Resource and Community Development Award specifically supports the creation of lasting research resources, stakeholder networks, and community infrastructure intended to continue benefiting the field beyond the award period.

What is the timeline to apply and when would I receive funding?

Concept Award

• Letter of Intent Deadline: 5:00 p.m. Eastern Time (ET), September 16, 2026

• Full Application Deadline: 11:59 p.m. ET, September 30, 2026

• Peer Review: December 2026

• Programmatic Review: March/April 2027

• Awards supported with FY26 funds will be made no later than September 30, 2027.

Idea Development Award

• Preproposal Deadline: 5:00 p.m. Eastern Time (ET), August 19, 2026

• Invitation to Submit Full Application: September 30, 2026

• Full Application Deadline: 11:59 p.m. ET, November 18, 2026

• Peer Review: February 2027

• Programmatic Review: March/April 2027

• Awards supported with FY26 funds will be made no later than September 30, 2027.

Resource and Community Development Award

• Preproposal Deadline: 5:00 p.m. Eastern Time (ET), August 19, 2026

• Invitation to Submit Full Application: September 30, 2026

• Full Application Deadline: 11:59 p.m. ET, November 18, 2026

• Peer Review: February 2027

• Programmatic Review: March/April 2027

• Awards supported with FY26 funds will be made no later than September 30, 2027.

Where does this funding come from?

The Rare Cancers Research Program is managed by the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development organization. Congress established the program in 2020 to support research of exceptional scientific merit in rare cancers. The FY26 appropriation is $17.5 million.

Who is eligible to apply?

Eligible applicants include:

• Foreign and domestic organizations

• For-profit organizations

• Nonprofit organizations

• Public entities

• Private entities

• Extramural and intramural organizations
  Principal Investigator eligibility varies by mechanism:

Concept Award

• Independent investigators at or above the level of postdoctoral fellow (or equivalent)

Idea Development Award

• Independent investigators at all career levels

Resource and Community Development Award

• Independent investigators at all career levels

Who is not eligible to apply?

The solicitation does not provide additional eligibility exclusions beyond the stated organizational and investigator requirements.

However:

• Awards are made to organizations, not individuals. - An investigator may only serve as Principal Investigator on one application within each FY26 RCRP award mechanism.

What companies and projects are likely to win?

The strongest applications will closely align with the intent of the selected mechanism.

Concept Award

• Highly innovative, untested, potentially groundbreaking concepts

• High-risk ideas that open entirely new avenues of investigation

• Novel approaches that challenge existing paradigms in rare cancers research

Idea Development Award

• Research supported by preliminary data

• Projects with strong scientific rationale

• Ideas capable of generating high-impact findings and major advancements in rare cancers research

Resource and Community Development Award

• Platforms, datasets, repositories, and infrastructure that fill major gaps in rare cancers research

• Projects with strong plans for community engagement, dissemination, sustainability, and resource sharing

• Efforts that can benefit multiple rare cancer types or subtypes

How competitive will this solicitation be?

The program is expected to be highly competitive.

Historical data provided in the solicitations show:

Concept Award

• 979 applications received

• 90 recommended for funding

Idea Development Award

• 862 applications received

• 85 recommended for funding

Resource and Community Development Award

• 103 applications received

• 23 recommended for funding

Are there any restrictions I should know about?

Across all three mechanisms:

• Clinical trials are not allowed. - Projects must focus on cancers affecting six or fewer persons per 100,000 people per year in the United States. - Research must be relevant to Service Members, Veterans, military beneficiaries, and the American public.
  Additional Resource and Community Development Award requirements include:

• At least two rare cancer Patient Advocates must participate as integral members of the research team.

• Community building, dissemination, and sustainability plans are required.

How long will it take me to prepare an application?

Preparation effort depends on the mechanism selected.

Concept Award

• Requires a Letter of Intent and a short blinded application package.

• Generally expected to require the least preparation effort of the three mechanisms.

Idea Development Award

• Requires a preproposal followed by an invited full application.

• Preliminary data with disease-specific rationale are required.
  Resource and Community Development Award

• Requires a preproposal followed by an invited full application.

• Requires extensive planning around community engagement, patient advocacy, dissemination, sustainment, and resource-sharing infrastructure.

How can BW&CO help?

BW&CO can support applicants with:

• Opportunity assessment and mechanism selection

• Eligibility and project fit review

• Preproposal and Letter of Intent development

• Full proposal writing and editing

• Scientific and commercialization positioning

• Reviewer-focused narrative development

• Patient advocate engagement strategy

• Budget development and compliance review

• Final submission support

Additional Resources

Review the solicitation here.

CDMRP: FY26 Kidney Cancer Research Program (KCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Department of Defense Congressionally Directed Medical Research Programs (CDMRP) has released three Fiscal Year 2026 Kidney Cancer Research Program (KCRP) funding opportunities designed to support innovative kidney cancer research, develop future leaders in the field, and accelerate new discoveries that improve outcomes for patients. Collectively, these opportunities represent approximately $10.2 million in anticipated funding across three award mechanisms.

The FY26 KCRP continues to focus on advancing the biology of kidney cancer, developing new therapeutic approaches, improving patient care and survivorship, addressing health disparities, and expanding research capacity through investigator development and collaboration.

Researchers can apply through one of three mechanisms:

Concept Award
Supports highly innovative, untested, and potentially groundbreaking ideas in kidney cancer research. This mechanism is intended for high-risk concepts that could open entirely new avenues of investigation. Preliminary data are not allowed. Awards provide up to $120,000 in total costs over one year.

Idea Development Award
Supports hypothesis-driven research projects backed by preliminary data and a well-developed scientific rationale. Projects must address important questions in kidney cancer research or clinical care and demonstrate potential for significant impact. Awards provide up to $900,000 for a single Principal Investigator or up to $1.2 million through the Partnering Principal Investigator option over three years.

Academy of Kidney Cancer Investigators – Early-Career Scholar Award
Supports promising early-career investigators pursuing independent careers in kidney cancer research. In addition to funding a research project, awardees join a national mentoring and networking academy that provides intensive mentorship, scientific collaboration opportunities, leadership development, and career support. Awards provide up to $1.2 million over four years.

All three mechanisms require submission of a Letter of Intent prior to full application submission and do not allow clinical trials. Applicants should begin preparing immediately to ensure sufficient time for project development, institutional approvals, collaborator coordination, and application assembly.

The earliest deadline is the Concept Award Letter of Intent due July 28, 2026, 5:00 p.m. Eastern Time. The Idea Development Award and Academy of Kidney Cancer Investigators – Early-Career Scholar Award both require Letters of Intent by September 14, 2026, 5:00 p.m. Eastern Time.

How much funding would I receive?

Funding depends on the mechanism selected.

Concept Award

• Up to $120,000 total costs

• Maximum period of performance: 1 year

• Approximately 7 awards anticipated

Idea Development Award

• Single PI Option: Up to $900,000 total costs

• Partnering PI Option: Up to $1.2 million total costs

• Maximum period of performance: 3 years

• Approximately 8 awards anticipated

Academy of Kidney Cancer Investigators – Early-Career Scholar Award

• Up to $1.2 million total costs

• Maximum period of performance: 4 years

• Approximately 2 awards anticipated

What could I use the funding for?

All three mechanisms support research addressing at least one FY26 KCRP focus area, including:

• Understanding kidney cancer biology, progression, metastasis, and prevention

• Developing new screening, diagnostic, prognostic, and imaging approaches

• Advancing treatments for rare kidney cancers

• Creating novel therapeutic strategies

• Improving quality of life and survivorship

• Addressing outcomes in high-risk and underserved populations

• Expanding research capacity and developing future kidney cancer researchers

The Concept Award is intended for exploratory, high-risk concepts.

The Idea Development Award supports mature research projects with preliminary data and a clearly defined hypothesis.

The Early-Career Scholar Award supports both a research project and a structured career-development program designed to establish long-term independence in kidney cancer research.

Are there any additional benefits I would receive?

The Idea Development Award includes a Partnering Principal Investigator option that supports formal collaborations between two investigators contributing distinct expertise to a single project.

The Academy of Kidney Cancer Investigators – Early-Career Scholar Award provides:

• Intensive mentorship from established kidney cancer investigators

• National networking opportunities

• Scientific collaborations

• Monthly academy programming

• Annual and biennial workshops

• Leadership and career development training

• Access to a national peer network of kidney cancer researchers

All three mechanisms encourage multidisciplinary collaborations involving academia, industry, the Department of Defense, the Department of Veterans Affairs, and other federal agencies.

What is the timeline to apply and when would I receive funding?

Concept Award

• Letter of Intent Deadline: July 28, 2026, 5:00 p.m. Eastern Time

• Application Deadline: August 11, 2026, 11:59 p.m. Eastern Time

• Peer Review: October 2026

• Programmatic Review: December 2026

Idea Development Award

• Letter of Intent Deadline: September 14, 2026, 5:00 p.m. Eastern Time

• Application Deadline: September 28, 2026, 11:59 p.m. Eastern Time

• Peer Review: December 2026

• Programmatic Review: March 2027

Academy of Kidney Cancer Investigators – Early-Career Scholar Award

• Letter of Intent Deadline: September 14, 2026, 5:00 p.m. Eastern Time

• Application Deadline: September 28, 2026, 11:59 p.m. Eastern Time

• Peer Review: December 2026

• Programmatic Review: March 2027

Awards funded through FY26 appropriations are expected to be made no later than September 30, 2027.

Where does this funding come from?

Funding comes from the Department of Defense Congressionally Directed Medical Research Programs through the Kidney Cancer Research Program.

Congress established the KCRP in 2017 to support research with exceptional scientific merit and high potential impact. The program received $15 million in FY26 appropriations.

The program's mission is to promote rigorous, innovative, high-impact kidney cancer research for the benefit of Service Members, Veterans, their families, and the American public.

Who is eligible to apply?

Concept Award

• Investigators at all career levels, including postdoctoral fellows or equivalent

• Foreign and domestic organizations

• For-profit and nonprofit organizations

• Public and private entities

Idea Development Award

• Investigators at or above the level of Assistant Professor (or equivalent)

• Foreign and domestic organizations

• For-profit and nonprofit organizations

• Public and private entities

Academy of Kidney Cancer Investigators – Early-Career Scholar Award

• Investigators within seven years of their most recent postdoctoral research position, clinical fellowship, or equivalent

• Must meet Early-Career Scholar eligibility requirements

• Must identify a qualified Designated Mentor

• Foreign and domestic organizations

• For-profit and nonprofit organizations

• Public and private entities

Who is not eligible to apply?

Concept Award

• Investigators below the postdoctoral fellow level (or equivalent)

Idea Development Award

• Investigators below the Assistant Professor level (or equivalent)

Academy of Kidney Cancer Investigators – Early-Career Scholar Award

• Individuals currently in postdoctoral positions, clinical fellowships, or equivalent training positions at the application deadline

• Investigators more than seven years removed from their last postdoctoral position, fellowship, or equivalent training experience

Additional eligibility restrictions apply to mentors participating in the Academy mechanism.

What companies and projects are likely to win?

Competitive applications will closely align with KCRP priorities and demonstrate clear potential to advance the field.

For the Concept Award, reviewers are looking for:

• Highly innovative ideas

• Novel concepts

• New research paradigms

• Research that goes beyond incremental advances

For the Idea Development Award, reviewers are looking for:

• Strong preliminary data

• Well-developed hypotheses

• Rigorous research strategies

• Significant potential impact on kidney cancer research or patient care

For the Early-Career Scholar Award, reviewers are evaluating:

• The investigator's potential to become an independent leader in kidney cancer research

• Quality of the mentoring plan

• Strength of the career-development strategy

• Scientific merit of the proposed research

Across all mechanisms, projects that directly address FY26 KCRP focus areas and demonstrate strong scientific rationale are likely to be most competitive.

Are there any restrictions I should know about?

Across all three mechanisms:

• Clinical trials are not allowed.

• Applications must address at least one FY26 KCRP focus area.

• Applications must address at least one eligible kidney cancer disease type.

• Cost sharing is not required.

• Awards are made to organizations rather than individuals.

Additional mechanism-specific restrictions include:

Concept Award

• Preliminary data are not allowed.

• Applications undergo blinded review.

• Applications may not contain identifying information about investigators or institutions.

Idea Development Award

• Preliminary data are required.

Academy of Kidney Cancer Investigators – Early-Career Scholar Award

• Preliminary data are required.

• Applicants must meet specific career-stage requirements.

• Applicants must identify an eligible Designated Mentor.

How competitive will this solicitation be?

The FY26 KCRP funding opportunities are expected to be highly competitive.

Historical funding data demonstrates significant demand:

Concept Award

• 587 applications received since FY17

• 73 recommended for funding

Idea Development Award

• 610 applications received since FY17

• 124 recommended for funding

Academy of Kidney Cancer Investigators – Early-Career Scholar Award

• 40 applications received since FY19

• 14 recommended for funding

Applicants should expect strong competition and should clearly demonstrate alignment with program priorities, innovation, feasibility, and potential impact.

How long will it take me to prepare an application?

Preparation effort varies significantly by mechanism.

Concept Award
Typically requires the least preparation because preliminary data are prohibited and the narrative is intentionally brief. However, applicants must carefully comply with blinded-review requirements.

Idea Development Award
Requires substantial preparation due to the need for preliminary data, a comprehensive research strategy, detailed supporting documentation, impact statements, and progression planning.

Academy of Kidney Cancer Investigators – Early-Career Scholar Award
Typically requires the greatest preparation effort because applicants must develop both a research plan and a comprehensive career-development strategy while coordinating mentor participation and institutional commitments.

How can BW&CO help?

BW&CO can help applicants determine which KCRP mechanism best aligns with their technology, scientific maturity, and career stage.

Our team can support:

• Opportunity assessment and go/no-go decisions

• Mechanism selection

• Research strategy development

• Hypothesis refinement

• Innovation positioning

• Impact narrative development

• Mentor and collaborator coordination

• Compliance review

• Proposal writing and editing

• Grants.gov and submission support

Additional Resources

Review the solicitation here.

Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This NIH opportunity (RFA-AI-27-014) supports the development of medical countermeasures (MCMs) and enabling technologies to address chemical and radiation/nuclear (CRN) threats in civilian settings. The program is administered by NIAID through the Radiation and Nuclear Countermeasures Program (RNCP) and Chemical Countermeasures Research Program (CCRP). It is designed to fund early and preclinical work that can diagnose, mitigate, or treat injuries following exposure.

This is a forecasted opportunity with an Estimated Application Due Date: October 9, 2026. Founders working in radiological, nuclear, or chemical threat preparedness should begin positioning now, as this is a complex NIH cooperative agreement with long lead times.

How much funding would I receive?

Funding amounts are not specified in the solicitation, but we anticipate funding to range from $500k - $2m.

What could I use the funding for?

Funding supports research and development of medical countermeasures and enabling technologies addressing CRN threats, including:

Radiation and Nuclear Countermeasures Program (RNCP):

• Radiation-focused models

• Biomarkers of radiation damage

• Devices to assess and predict injury

• Products to improve survival and reduce morbidity across organ systems

Chemical Countermeasures Research Program (CCRP):

• Preclinical development of products

• Technologies to mitigate or treat injury after exposure to Chemicals of Concern

• Solutions designed for post-exposure, civilian mass casualty settings

All work must align with developing capabilities to diagnose, mitigate, or treat acute and delayed effects of radiation or chemical exposure during or after public health emergencies.

Are there any additional benefits I would receive?

• Not specified in the solicitation.

What is the timeline to apply and when would I receive funding?

• Estimated Post Date: July 10, 2026

• Estimated Application Due Date: October 9, 2026

• Estimated Award Date: July 1, 2027

• Estimated Project Start Date: July 1, 2027

Additional timeline details are not specified in the solicitation.

Where does this funding come from?

This funding is provided by the National Institute of Allergy and Infectious Diseases (NIAID) on behalf of the NIH.

It is authorized under:

• Sections 301 and 405 of the Public Health Service Act (42 USC 241 and 284)

• Federal Regulations: 42 CFR Part 52 and 2 CFR Part 200

The program is supported by a congressional mandate (Public Law 109-149, Dec. 30, 2005) to advance research addressing chemical and radiological threats.

Who is eligible to apply?

For-profit:

• Small businesses

• For-profit organizations other than small businesses

What companies and projects are likely to win?

Projects that align closely with the stated program goals, including:

• Development of medical countermeasures for radiation or chemical exposure

• Technologies addressing post-exposure treatment in civilian mass casualty scenarios

• Preclinical-stage innovations with clear pathways to mitigating injury or improving survival

• Tools for diagnostics, biomarkers, or injury assessment

Further selection criteria are not specified in the solicitation.

Are there any restrictions I should know about?

• Funding instrument is a cooperative agreement

• No cost sharing or matching requirement

Additional restrictions are not specified in the solicitation.

How long will it take me to prepare an application?

Given this is an NIH cooperative agreement focused on preclinical and translational research, preparation timelines are typically substantial, but exact expectations are not specified in the solicitation.

How can BW&CO help?

BW&CO can support:

• Translating your technology into NIH-aligned positioning

• Mapping your solution to RNCP or CCRP priorities

• Structuring a competitive preclinical development narrative

• Managing the full application process ahead of the October 9, 2026 deadline

Additional Resources

Review solicitation here.

CDMRP: FY26 Epilepsy Research Program (ERP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Epilepsy Research Program (ERP) from the Congressionally Directed Medical Research Programs (CDMRP), managed by the Defense Health Agency Research and Development – Medical Research and Development Command, is expected to fund innovative research focused on post-traumatic epilepsy (PTE) and related comorbidities.

The program’s goal is to improve quality of life for Service Members, Veterans, caregivers, and the broader epilepsy community by advancing understanding of the biological mechanisms, epidemiology, progression, and treatment of PTE.

This announcement is a pre-announcement, meaning investigators should begin preparing ideas now. Application deadlines have not yet been released. The official Funding Opportunity Announcements (FOAs), which will include submission deadlines, will be posted on Grants.gov.

How much funding would I receive?

Funding amounts depend on the award mechanism.

• Idea Development Award

  • Maximum funding: $1 million total costs

  • Maximum period of performance: 3 years

• Leveraging Research Award

  • Maximum funding: $800,000 total costs

  • Maximum period of performance: 3 years

• Research Partnership Award

  • Maximum funding: $2 million total costs

  • Maximum period of performance: 3 years

• Virtual Post-Traumatic Epilepsy Research Center – Leadership Award

  • Maximum funding: $1.6 million total costs

  • Maximum period of performance: 4 years

• Virtual Post-Traumatic Epilepsy Research Center – Faculty Award

  • Maximum funding: $800,000 total costs

  • Maximum period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

ERP funding supports research designed to advance understanding of post-traumatic epilepsy (PTE) and related conditions. Applications should address at least one of the program’s focus areas:

Markers and Mechanisms of PTE

• Identification of biomarkers predicting epilepsy development

• Research into biological mechanisms that could prevent epileptogenesis or seizure activity

Epidemiological Characterization of PTE

• Identifying predictors of epilepsy development

• Studying patient outcomes such as latency to epilepsy onset, comorbidities, and mortality

• Measuring impacts on quality of life for patients and caregivers

Longitudinal Studies of PTE Progression

• Tracking disease progression over time

• Evaluating treatment outcomes and quality of care

• Studying interactions between epilepsy and comorbid conditions such as psychiatric disorders, cognitive deficits, sleep disorders, and fatigue

Innovative Research Tools and Technologies

• Artificial intelligence or bioinformatics tools

• Clinical databases and advanced device technologies for seizure detection and diagnosis

• Models for studying post-traumatic epilepsy

• Tools enabling future clinical trials

Are there any additional benefits I would receive?

Some award mechanisms provide benefits beyond funding.

For example:

• Research Partnership Award

  • Supports collaborative research between two named Principal Investigators

• Virtual Post-Traumatic Epilepsy Research Center – Leadership Award

  • Provides funding to lead a virtual research center

  • Includes responsibilities such as mentoring investigators and facilitating collaboration

• Virtual Post-Traumatic Epilepsy Research Center – Faculty Award

  • Supports early-career researchers or investigators new to the PTE field

  • Includes mentorship and career development within a collaborative research environment

What is the timeline to apply and when would I receive funding?

The process will include:

• Pre-application submission through eBRAP

• Pre-applications will be Letters of Intent

• Full applications will follow the requirements outlined in the final FOAs on Grants.gov

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act, which provides funding for the Epilepsy Research Program (ERP).

The program is administered by:

• Congressionally Directed Medical Research Programs (CDMRP)

• Defense Health Agency Research and Development – Medical Research and Development Command

ERP focuses on research that benefits Service Members, Veterans, caregivers, and the broader epilepsy community.

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Idea Development Award

  • Independent investigators at any career level may serve as Principal Investigator

• Leveraging Research Award

  • Independent investigators at any career level may serve as Principal Investigator

• Research Partnership Award

  • Two named Principal Investigators who are independent investigators at any career level

• Virtual P-TERC Leadership Award

  • Director and Deputy Director must be independent investigators with:

    • Strong history of PTE research funding

    • Peer-reviewed publications

    • Mentorship experience

• Virtual P-TERC Faculty Award

  • Early-career investigators or investigators new to the PTE field

What companies and projects are likely to win?

ERP prioritizes research that:

• Advances understanding of post-traumatic epilepsy and associated comorbidities

• Improves quality of life for Service Members, Veterans, and caregivers

• Demonstrates innovation or high creativity

• Challenges existing research paradigms

• Leverages existing datasets, cohorts, or research infrastructure

• Includes strong collaborations where appropriate

Are there any restrictions I should know about?

Key requirements include:

• Pre-applications must be submitted through eBRAP

• All pre-applications are Letters of Intent

• Full applications must follow the requirements of the final Funding Opportunity Announcements on Grants.gov

• Applications must align with the ERP’s focus areas on post-traumatic epilepsy

How long will it take me to prepare an application?

Preparation time will depend on the complexity of the project and research team.

Typical CDMRP submissions involve:

• A Letter of Intent (pre-application)

• A full application including research plan, budget, and supporting documentation

Because official deadlines have not yet been released, investigators should begin developing project concepts now so they are ready once the FOAs are posted.

How can BW&CO help?

BW&CO supports companies and research teams pursuing CDMRP and other federal research funding by:

• Identifying the most competitive award mechanism

• Developing a compelling proposal narrative aligned with program priorities

• Structuring the research plan and milestones

• Coordinating multi-institution collaborations

• Managing the full submission process through eBRAP and Grants.gov

Our team has extensive experience helping applicants pursue defense health and biomedical research funding.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Alzheimer’s Research Program (AZRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 (FY26) Alzheimer’s Research Program (AZRP) is expected to release funding opportunities through the Congressionally Directed Medical Research Programs (CDMRP) to support impactful research addressing Alzheimer’s disease and Alzheimer’s disease–related dementias (AD/ADRD).

06-22-2026 - (Pre-application - Pre-Proposal)
09-24-2026 - (Application)

The program’s mission is to fund solution-oriented research that improves quality of life for people living with Alzheimer’s disease and related dementias, including Service Members, Veterans, their Families, and the general public.

Congress appropriated $15.0 million for the FY26 Alzheimer’s Research Program.

The FY26 AZRP is expected to support research that improves diagnosis, prevention, risk reduction, and quality of life for individuals affected by AD/ADRD.

How much funding would I receive?

Funding depends on the award mechanism.

Transforming Care Award

• Maximum funding: $1.6M total costs

• Maximum period of performance: 4 years

Career Initiation or Transition Partnership Option (CITPO):

• Maximum funding: $1.8M total costs

• Maximum period of performance: 4 years

Transforming Diagnosis Award

• Maximum funding: $1.5M total costs

• Maximum period of performance: 4 years

Career Initiation or Transition Partnership Option (CITPO):

• Maximum funding: $1.7M total costs

• Maximum period of performance: 4 years

Transforming Research Award

• Maximum funding: $1M total costs

• Maximum period of performance: 3 years

What could I use the funding for?

Funding supports non-incremental, solution-focused research addressing Alzheimer’s disease and related dementias (AD/ADRD).

The allowable research depends on the mechanism.

Transforming Care Award

Supports well-designed non-incremental clinical research or clinical trials in dementia care that provide solutions for individuals living with AD/ADRD.

Projects may address:

• Care interventions

• Strategies or technologies for dementia care

• Tools that improve daily living and support systems

• Approaches that reduce caregiver burden and stress

• Methods that improve quality of life for individuals with dementia

Applications are encouraged to prioritize both:

• Individuals living with AD/ADRD

• Their care partners

Transforming Diagnosis Award

Supports solutions-oriented research addressing barriers to diagnosis, disease monitoring, or prognosis.

Barriers may include:

• Diagnostic technologies

• Cost barriers

• Access to diagnostic tools

• Clinical implementation challenges

• Biomarker validation

• Disease monitoring methods

• Lack of longitudinal data for prediction or prognosis

Research may include:

• Prospective human subject recruitment

• De-identified human samples, specimens, or datasets

Transforming Research Award

Supports research that reduces risk and prevents the development of AD/ADRD.

Applications must address one of two focus areas:

Risk factor knowledge

• Identification or validation of risk or protective factors

• Environmental, epigenetic, genetic, lifestyle, or occupational risks

Risk reduction solutions

• Non-pharmacological methods

• Technologies

• Prevention strategies that reduce risk of AD/ADRD

The program encourages studies leveraging existing cohorts or datasets, including cohorts 65 years or younger.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional non-funding benefits.

However, CDMRP programs typically provide:

• Access to a two-tier review system combining scientific peer review and programmatic review to ensure scientific merit and mission relevance.

• Opportunities to collaborate with researchers, clinicians, and community stakeholders affected by the disease.

What is the timeline to apply and when would I receive funding?

06-22-2026 - (Pre-application - Pre-Proposal)
09-24-2026 - (Application)

Where does this funding come from?

This funding comes from the Congressionally Directed Medical Research Programs (CDMRP) within the Department of Defense.

Key facts:

• Funding was appropriated through the Consolidated Appropriations Act, 2026.

• CDMRP manages biomedical research programs supporting the health of Service Members, Veterans, their Families, and the American public.

Who is eligible to apply?

Detailed eligibility criteria will be provided in the official Funding Opportunity Announcements.

What companies and projects are likely to win?

The AZRP supports projects that:

• Address critical needs in Alzheimer’s disease and related dementias

• Deliver solution-oriented outcomes

• Improve diagnosis, prevention, or patient quality of life

• Demonstrate clear relevance to Service Members, Veterans, their Families, or the broader public

Projects that show strong scientific merit and mission relevance are prioritized through CDMRP’s two-tier review process.

Are there any restrictions I should know about?

Restrictions and requirements are not specified in the pre-announcement.

These details—including allowable costs, research scope limitations, and regulatory requirements—will be defined in the full Funding Opportunity Announcements.

How long will it take me to prepare an application?

The preparation timeline is not specified in the pre-announcement.

CDMRP programs often use a two-stage process that may include:

• Pre-application submission

• Invitation to submit a full application

However, the specific process for FY26 AZRP is not specified in the pre-announcement.

How can BW&CO help?

BW&CO supports teams pursuing CDMRP funding by:

• Assessing project fit with the AZRP mission and research priorities

• Developing a competitive technical narrative

• Structuring proposals to align with CDMRP review criteria

• Managing submission strategy, compliance, and timeline

• Coordinating collaborators, investigators, and supporting documentation

Our team has extensive experience supporting Department of Defense CDMRP grant applications.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Autism Research Program

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 (FY26) Autism Research Program (ARP) from the Congressionally Directed Medical Research Programs (CDMRP) will fund innovative, high-impact research with clinical relevance that improves outcomes for individuals with autism and their families. The program released this pre-announcement to allow investigators time to plan proposals before the formal Funding Opportunity Announcements (FOAs) are released.

The FY26 ARP was funded through the FY26 Defense Appropriations Act. Investigators should begin preparing now because the program will require a pre-application before submission of a full proposal once the FOAs are released.

Application deadline: The deadline is not specified in the solicitation. Deadlines will be published in the FY26 ARP funding opportunity announcements when they are released on Grants.gov.

How much funding would I receive?

Funding depends on the specific award mechanism.

Career Development Award

• Maximum funding: $750,000 total costs

• Maximum period of performance: 3 years

Clinical Trial Award

• Maximum funding: $1.5 million total costs

• Maximum period of performance: 4 years

Clinical Trial Award – Nested Early-Career Investigator Option

• Maximum funding: $1.75 million total costs

• Maximum period of performance: 4 years

Idea Development Award

• Maximum funding: $750,000 total costs

• Maximum period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Each mechanism supports different types of autism research.

Career Development Award

• Supports early-career independent investigators or established investigators transitioning into autism research.

• Projects must pursue research with the potential to have a major impact on autism.

• Supported activities include:

  • Innovative, high-impact research ideas

  • Early-phase, proof-of-principle clinical trials

• Preliminary data is required.

Clinical Trial Award

• Supports research with the potential to have a major impact on the treatment and/or management of autism.

• Projects must involve clinical trials supported by preliminary data.

Clinical Trial Award – Nested Early-Career Investigator Option

• Allows a senior investigator (initiating PI) to collaborate with a young investigator.

• Supports the development of investigators pursuing careers in autism clinical trial research.

Idea Development Award

• Supports innovative, high-impact ideas that advance understanding of autism and lead to improved outcomes.

• Includes a Partnering PI Option allowing collaboration between two investigators.

• Clinical trials are not allowed under this mechanism.

All mechanisms require preliminary data relevant to the proposed project.

Are there any additional benefits I would receive?

The program includes several structural benefits:

• Career Development Award supports the transition of researchers into the autism field.

• Clinical Trial Award – Nested Early-Career Investigator Option provides structured development for young investigators.

• Idea Development Award – Partnering PI Option encourages collaboration between investigators.

These structures are designed to expand the autism research workforce and accelerate impactful research.

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: March 2, 2026

• Funding Opportunity Announcements (FOAs) will be posted on Grants.gov.

• Pre-application submission through eBRAP is required before submitting a full application.

• Application submission is by invitation only after review of the pre-application.

• Pre-application and full application deadlines are not specified in the pre-announcement.

• Funding start dates are not specified in the pre-announcement.

Where does this funding come from?

Funding for the program comes from the FY26 Defense Appropriations Act and is administered by the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development – Medical Research and Development Command.

The program is part of the Department of Defense’s Autism Research Program (ARP).

Who is eligible to apply?

Eligibility varies by mechanism.

Career Development Award
Applicants must:

• Be independent investigators at or below the level of Assistant Professor, or equivalent,

  or

• Be established investigators in a field other than autism at or above the level of Assistant Professor seeking to transition into autism research.

Additional requirements:

• Must not have previously received a Career Development Award (or equivalent) from any CDMRP program or other federal agency.

• Must not have received more than $250,000 in total direct costs for previous or concurrent autism research as a PI of federally or privately funded non-mentored peer-reviewed grants.

• Must hold a Ph.D., M.D., M.D./Ph.D., or equivalent at the time of pre-application submission.

• Must not be a graduate student, postdoctoral fellow, or other mentored researcher.

Clinical Trial Award

• Independent investigators at any career level.

Clinical Trial Award – Nested Early-Career Investigator Option
Young investigator must:

• Be currently in postdoctoral training or have completed postdoctoral training.

• Be no more than 7 years from receipt of a terminal degree.

• Commit at least 50% time to the project.

Idea Development Award

• Independent investigators at any career level.

What companies and projects are likely to win?

Based on the pre-announcement, competitive applications will likely:

• Propose innovative, high-impact research addressing autism

• Demonstrate strong preliminary data

• Show potential for major impact on understanding, treatment, or management of autism

• Align with the goals of the specific award mechanism

• For collaboration options, demonstrate meaningful partnerships between investigators

Applications must clearly demonstrate scientific merit and potential impact.

Are there any restrictions I should know about?

Key restrictions include:

• Pre-application submission through eBRAP is required before submitting a full application.

• Full applications are submitted by invitation only.

• Preliminary data is required for all mechanisms.

• Idea Development Award applications cannot support clinical trials, including a clinical trial aim.

• Career Development Award applicants must meet prior funding and career stage restrictions.

All applications must conform to the final Funding Opportunity Announcements posted on Grants.gov.

How long will it take me to prepare an application?

The solicitation does not specify preparation time.

However, because the ARP uses a two-stage process (pre-application followed by invitation-only full application), applicants typically need time to:

• Prepare a competitive pre-proposal

• Develop preliminary data and a detailed research plan

• Assemble collaborators and institutional approvals

Investigators are encouraged to begin planning early before FOAs are released.

How can BW&CO help?

BW&CO can support applicants throughout the ARP application process, including:

• Evaluating project fit with ARP mechanisms

• Developing a competitive proposal strategy

• Structuring impact-focused research narratives

• Managing the pre-application and full application process

• Preparing supporting documents and compliance materials

• Coordinating multi-investigator collaborations

Our team has extensive experience supporting Department of Defense CDMRP grant applications.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Lung Cancer Research Program (LCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now to prepare for the FY26 Lung Cancer Research Program (LCRP) funding opportunities — anticipated to open on Grants.gov imminently. This chance is critical for investigators aiming to drive innovative, high-impact research that will eradicate deaths and suffering from lung cancer, with a focus on outcomes that benefit Service Members, Veterans, their families, and the general public. Exact pre-application and application deadlines will be posted in the final NOFOs on Grants.gov when released.

Pre-Applications are due on 6/23/26 and 8/18/26.

Full Applications are due on 9/02/26.

How much funding would I receive?

Award amounts for the FY26 LCRP are specified by mechanism:

• Idea Development Award: Up to $800,000 total costs over 3 years.

• Translational Research Award (Level 1): Up to $1.35M total costs over 3 years.

• Translational Research Award (Level 2 – Clinical Trial Option): Up to $1.85M total costs over 4 years.

• Patient-Centered Outcomes and Survivorship Award: Up to $975,000 total costs over 3 years.

What could I use the funding for?

Funding supports research in the following Areas of Emphasis:

• Biology & Etiology: Mechanisms of lung cancer initiation and progression.

• Prevention & Risk Reduction: Innovative prevention and recurrence reduction strategies.

• Detection, Diagnosis & Surveillance: Improved early detection and disease monitoring.

• Treatment & Prognosis: Novel treatments, biomarkers, and metastasis management.

• Health Outcomes & Survivorship: Survivorship quality of life, comorbidity impacts, and disparities reduction.

Each mechanism has specific focus and eligibility criteria detailed in the forthcoming NOFOs.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional benefits (e.g., data resources or training support). These may be described in the final funding opportunity announcements.

What is the timeline to apply and when would I receive funding?

• Pre-Applications are due on 6/23/26 and 8/18/26.

• Full Applications are due on 9/02/26.

Where does this funding come from?

Funding arises from the FY26 Defense Appropriations Act and is administered through the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development.

Who is eligible to apply?

Eligibility (e.g., investigator types, institution requirements) will be outlined in the final NOFOs. The pre-announcement does not include full eligibility details.

What companies and projects are likely to win?

Applicants are more competitive if they:

• Align tightly with one or more Areas of Emphasis.

• Demonstrate innovation and potential clinical impact.

• Address relevance to military health (e.g., Veteran populations, exposures).

Are there any restrictions I should know about?

• Some mechanisms (e.g., Idea Development) do not allow clinical trials.

• Specific restrictions and requirements will be in the NOFOs once released.

How long will it take me to prepare an application?

Preparation time depends on the mechanism, project maturity, and whether preliminary data or partnerships are needed. Start planning now to align with the mechanisms and Areas of Emphasis.

How can BW&CO help?

BW&CO can help you:

• Decode the final NOFO requirements.

• Align your research strategy to maximize impact.

• Draft and polish pre-applications/ applications.

• Manage submission logistics and compliance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Orthopaedic Research Program (ORP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Orthopaedic Research Program (ORP) pre-announcement outlines anticipated funding opportunities supporting innovative, high-impact research to advance treatment and rehabilitation for orthopaedic injuries sustained during combat and service-related activities. This pre-announcement is intended to help teams plan now; it is not a promise of funding. Full Funding Opportunity Announcements (FOAs) with submission deadlines will be posted on Grants.gov and eBRAP when released.

Pre-Application (Preproposal): August 19th

Application: November 18th

How much funding would I receive?

Specific award budgets and totals are not yet provided in the pre-announcement. A sampling of anticipated mechanisms includes:

• Applied Research Award – up to $950,000 total costs over up to 3 years.

• Clinical Research Award (Level 1) – up to $2,000,000 total costs (4-year max).

• Clinical Research Award (Level 2) – up to $3,200,000 total costs (4-year max).
  (Total awards by mechanism and number of awards are not specified at this stage.)

What could I use the funding for?

Projects must address one or more of the FY26 ORP focus areas, including:

• Battlefield fracture-related infection (prevention, early detection, eradication strategies).

• Composite tissue regeneration following high-energy extremity trauma.

• Ligamentous trauma treatments for musculoskeletal soft-tissue instability.

• Limb stabilization and wound protectants enabling prolonged care.

• Osseointegration outcomes for prosthetic limb interfaces.

• Return-to-duty strategies to optimize reintegration and reduce reinjury.

• Military women’s health impacts of orthopaedic care.
  Funding applies to research that improves patient function, restores mobility, and maximizes return to duty in military and service-related contexts.

Are there any additional benefits I would receive?

The pre-announcement does not list additional benefits (e.g., mentoring, training, networking) beyond funding support.

What is the timeline to apply and when would I receive funding?

• Pre-announcement release:February 24, 2026.

• FOAs release: Posted later on Grants.gov and eBRAP (dates not yet specified).

• Pre-Application (Preproposal): August 19th

• Application: November 18th

• Funding start dates: Determined after FOA release and award negotiations (not specified).
  (All deadlines and schedules will be in the final FOAs — not provided in this pre-announcement.)

Where does this funding come from?

Funding is authorized by the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) through the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility for each award mechanism will be defined in the full FOAs. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms, particularly clinical research awards.

• Preproposal required: Some mechanisms require a preproposal through eBRAP, and full application is by invitation only.
  (Complete eligibility details — including institution types, citizenship, and cost share — will be in the FOAs and are not specified here.)

What companies and projects are likely to win?

Specific companies or project profiles most likely to win are not described in the pre-announcement. Competitive applications will align with the ORP focus areas and demonstrate potential to advance orthopaedic care in military and clinical contexts.

Are there any restrictions I should know about?

• The ORP will not consider applications proposing strategies infeasible in battlefield environments for fracture-related infection or tissue regeneration alone.

• The program will not consider biomarker-only research.

• Preproposal submission is required for certain mechanisms; full applications may be by invitation only.

• All submissions must comply with final FOA instructions posted on Grants.gov.

How long will it take me to prepare an application?

With deadlines and FOA details not yet posted, exact preparation time cannot be stated. Given CDMRP’s typical structure, planning should begin now to develop compelling science narratives, compliance documents, and required eBRAP preproposals.

How can BW&CO help?

BW&CO can help you:

• Monitor FOA release dates and mechanism details.

• Translate the final FOA into a targeted application roadmap.

• Develop high-impact narrative, budget, and compliance materials.

• Guide submission strategy on eBRAP and Grants.gov.

• Support preproposal and full application review to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

ARPA-H SSO: “AGENTIC AI-ENABLED CARDIOVASCULAR CARE TRANSFORMATION” (ADVOCATE)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

ARPA-H is now accepting proposals for ADVOCATE: Agentic AI-Enabled Cardiovascular Care Transformation, a major new Innovative Solutions Opening (ISO) focused on deploying autonomous, FDA-regulated clinical AI agents for cardiovascular disease (CVD) care at national scale.

This program is designed to fund teams that can build, validate, and deploy patient-facing AI agents, paired with independent supervisory AI, and integrate them directly into real healthcare systems. Selected performers will work closely with FDA, large health systems, and ARPA-H leadership to establish a blueprint for scalable, reimbursable agentic AI in healthcare. A Solution Summary is mandatory and is due February 27, 2026, at 5:00 PM EST. Full proposals are by invitation only and are due April 1, 2026, at 5:00 PM EST.

How much funding would I receive?

• Total award size: Not specified in the solicitation

• Number of awards: Multiple awards anticipated

• Funding mechanism: Other Transaction (OT) Agreements

• Program length: Up to 39 months

  • Phase 1A: 12 months

  • Phase 1B: 12 months (option)

  • Phase 2: 15 months (option)

What could I use the funding for?

Funding must support development, validation, and deployment of agentic AI systems for cardiovascular care, aligned to one or more of the following Technical Areas (TAs):

TA1 — CVD Agent (Patient-Facing Clinical AI)

• Autonomous or semi-autonomous AI agents that:

  • Provide diagnostic and treatment assistance

  • Adjust prescriptions for CV conditions (FDA medical device)

  • Integrate real-time EHR and wearable data

  • Deliver 24/7 outpatient care management

• Clinical reasoning using multimodal inputs (text, voice, image, video)

• FDA regulatory engagement and authorization

• Deployment into real health systems for scalability studies

TA2 — Supervisory Agent (AI Oversight & Control)

• Disease-agnostic AI that:

  • Monitors safety, accuracy, uncertainty, and risk of clinical AI

  • Enables real-time control and auditability

  • Supports FDA Medical Device Development Tool (MDDT) qualification

• Continuous post-market monitoring functionality

• Strong preference for open-source solutions

TA3 — Scaled Implementation (Health Systems Only)

• Integration of TA1 and TA2 agents into live clinical workflows

• Access to EHR production and pre-production environments

• Execution of large-scale Scalability Studies

• Clinical outcome, cost, and reimbursement evidence generation

Are there any additional benefits I would receive?

Selected teams receive:

• Direct engagement with FDA throughout development

• Access to real EHR data, clinicians, and patients (via TA3 performers)

• Participation in large, ARPA-H-funded scalability studies

• Validation by an independent IV&V partner

• Visibility with payers and CMS-relevant evidence generation

• Potential facilitation of investor engagement by ARPA-H

What is the timeline to apply and when would I receive funding?

Key dates (firm):

• Posting date: January 13, 2026

• Proposers’ Day: January 23, 2026 (8:30 AM – 5:00 PM EST)

• Proposers’ Day registration deadline:

  • In-person: January 21, 2026, at 5:00 PM EST

  • Virtual: January 21, 2026, at 5:00 PM EST

• Solution Summary due: February 27, 2026, at 5:00 PM EST

• Full proposal due (if invited): April 1, 2026, at 5:00 PM EST

Funding timing after submission is not specified and is contingent on negotiations and down-selection decisions.

Where does this funding come from?

• Agency: Advanced Research Projects Agency for Health (ARPA-H)

• Office: Scalable Solutions Office (SSO)

• Authority: Other Transaction (OT)

Who is eligible to apply?

Eligible applicants include:

• U.S. startups and growth-stage companies

• Universities and academic teams

• Non-profit organizations

• Non-federal research organizations

Not eligible:

• Federally Funded Research and Development Centers (FFRDCs)

• Federal government entities or employees (as performers)

• Entities from covered foreign countries or foreign entities of concern

• Organizations with unmitigable ARPA-H conflicts of interest

TA3 applicants cannot apply to TA1 or TA2.

What companies and projects are likely to win?

ARPA-H is explicitly seeking teams that:

• Are building agentic (not rules-based) clinical AI

• Can meet FDA medical device or MDDT requirements

• Have real experience integrating with EHRs and health systems

• Can demonstrate a path to non-inferiority vs cardiologists

• Are prepared for open data sharing and multi-party collaboration

• Can scale beyond pilots into national deployment

Incremental clinical decision support tools are unlikely to be competitive.

Are there any restrictions I should know about?

Key restrictions include:

• Foundation models cannot be developed from scratch

• Solutions must be interoperable with other agents

• Clinical AI must pursue FDA authorization or qualification

• Extensive data-sharing and collaboration are mandatory

• Foreign talent, ownership, or funding risks are heavily scrutinized

• TA1 and TA2 proposals must remain technically independent

How long will it take me to prepare an application?

• Solution Summary: ~2–4 weeks for competitive teams

• Full Proposal: ~6–10 weeks if invited

Team formation, regulatory strategy, and data architecture must be addressed early.

How can BW&CO help?

BW&CO helps teams:

• Translate ADVOCATE requirements into a clear, fundable narrative

• Position technical capabilities against TA-specific metrics

• Shape FDA and commercialization strategy language

• Design compliant multi-party teaming structures

• Avoid common ARPA-H disqualifiers

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.